| Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. | |
| | |
MedLine Citation:
|
PMID: 22419641 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This open-label randomized trial compared isoniazid (9 months) to rifampin (4 months) on toxicity and completion in a jailed population with latent tuberculosis infection. Rifampin resulted in fewer elevated liver function tests (risk ratio [RR] 0.39, 95% confidence interval [CI] [0.18, 0.86]) and less toxicity requiring medication withdrawal (RR 0.51, 95% CI [0.13, 2.01]), although one participant receiving rifampin experienced an allergic reaction. Completion was achieved for 33% receiving rifampin compared to 26% receiving isoniazid (p = .10). With careful monitoring rifampin is a safe and less toxic regimen and appears to be a reasonable alternative because of its shorter duration, allowing more people to complete treatment behind bars. Therapy completion in released inmates is unacceptably low and ensuring follow-up after discharge must be part of a decision to treat. |
| | |
Authors:
|
Mary C White; Jacqueline P Tulsky; Ju Ruey-Jiuan Lee; Lisa Chen; Joe Goldenson; Joanne Spetz; L Masae Kawamura |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural Date: 2012-03-14 |
Journal Detail:
|
Title: Journal of correctional health care : the official journal of the National Commission on Correctional Health Care Volume: 18 ISSN: 1940-5200 ISO Abbreviation: J Correct Health Care Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-05-11 Completed Date: 2012-09-17 Revised Date: 2013-02-26 |
Medline Journal Info:
|
Nlm Unique ID: 9503759 Medline TA: J Correct Health Care Country: United States |
Other Details:
|
Languages: eng Pagination: 131-42 Citation Subset: IM |
Affiliation:
|
Department of Community Health Systems, School of Nursing, University of California, San Francisco, CA 94143, USA. mary.white@nursing.ucsf.edu |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00128206 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antitubercular Agents / administration & dosage, adverse effects, therapeutic use* Directly Observed Therapy Female Humans Isoniazid / administration & dosage, adverse effects, therapeutic use* Latent Tuberculosis / drug therapy* Liver Function Tests Male Medication Adherence Prisons* Rifampin / administration & dosage, adverse effects, therapeutic use* Socioeconomic Factors |
| Grant Support | |
ID/Acronym/Agency:
|
U01 AI 51315/AI/NIAID NIH HHS; U01 AI051315-01A1/AI/NIAID NIH HHS; U01 AI051315-02/AI/NIAID NIH HHS; U01 AI051315-03/AI/NIAID NIH HHS; U01 AI051315-04/AI/NIAID NIH HHS; U01 AI051315-04S1/AI/NIAID NIH HHS; U01 AI051315-04S2/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antitubercular Agents; 13292-46-1/Rifampin; 54-85-3/Isoniazid |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Contraceptive Use and Barriers to Access Among Newly Arrested Women.
Next Document: Chlamydia and Gonorrhea Screening Using Urine-Based Nucleic Acid Amplification Testing Among Males E...